PSYCHEDELICS INDUSTRY ACHIEVES INVESTMENT MILESTONE
Last week, the world’s first exchange-traded fund for psychedelic-drug companies launched in Toronto, as the investment industry aims to capitalise on rising interest in prospective mental health treatments using psychedelic medicines and therapies.
The Horizons Psychedelic Stock Index ETF, listed as PSYK, has been trading on the NEO Exchange.
BUSINESS AND INVESTMENT
Cybin announces C$20 million bought-deal offering to fund clinical trials with psychedelics.
Red Light Holland announces closing of C$9.77 million bought-deal financing.
MindMed announces reorganisation of leadership.
CannaGlobal rebrands as GoodCap Wellness, focusing on psilocybin mushrooms.
Havn Life announces deal to supply psychedelics for clinical trials to HealthTech Connex Inc.
EXPERTS WEIGH IN ON THE FUTURE OF THE PSYCHEDELICS INDUSTRY
During The PSYCH Symposium in November 2020, a panel of leading experts, operating in psychedelics sector discussed the advancement of research on psilocybin.
The groundbreaking, rapid progress being made in a number of regions across the US and beyond, the panel examined the realistic steps being taken towards the development of psychedelic treatment centres and how the business world is preparing for it.
REGULATION & LEGISLATION
ACCESS A COMPREHENSIVE OVERVIEW OF PSYCHEDELICS
Psychedelic medicines are becoming increasingly mainstream around the world as a result of significant progress being made in clinical trials and public perception shifting in favour of new and innovative therapies.
This report contains:
- Proprietary consumer insights on attitudes, uses and behaviours
- Deep dives into the most transformative compounds and companies
- Key regulations, transformative trends and commercial opportunities
RESEARCH & SCIENCE
Heroic Hearts Project UK launch short documentary that explores psychedelics as medicine with army veteran Guy Murray.
Atai to work with Massachusetts Hospital to study psychedelics for mental health disorders.